GlycoMimetics and Crescent Biopharma: A Merger for Cancer Innovation

GlycoMimetics and Crescent Biopharma have announced plans to merge, creating a new entity focused on advancing innovative cancer therapies. The merger, expected to close in the second quarter of 2025, will combine GlycoMimetics' expertise in glycomimetic drug discovery with Crescent's pipeline of precision-engineered biologics. The new company will operate under the name Crescent Biopharma and will be led by Jonathan Violin, Crescent's interim CEO and Venture Partner at Fairmount.

Crescent Biopharma's lead program, CR-001, is a tetravalent PD-1 x VEGF bispecific antibody that incorporates a cooperative binding mechanism. This mechanism has demonstrated superior efficacy to the anti-PD-1 antibody pembrolizumab in a third-party head-to-head Phase 3 clinical trial. The specific level of cooperativity engineered into CR-001 reflects a delicate mechanistic balance, which is essential to the confidence in this program. The nature of the PD-1xVEGF opportunity means that being as good as or even better than other molecules in the PD-1xVEGF space may be good enough to secure a significant market share.

The merger is supported by a $200 million financing round led by a syndicate of investors, including Fairmount, Venrock Healthcare Capital Partners, BVF Partners, and others. This funding will enable Crescent Biopharma to advance its lead program, CR-001, through preliminary proof-of-concept clinical data in solid tumor patients, expected in the second half of 2026. The financing will also support the development of Crescent's two novel antibody-drug conjugates (ADCs), CR-002 and CR-003, which use topoisomerase inhibitor payloads and have shown improved efficacy and safety compared to ADCs with alternative payloads.

Crescent Biopharma's pipeline also includes two novel antibody-drug conjugates with topoisomerase inhibitor payloads, CR-002 and CR-003. These ADCs have shown improved efficacy and safety compared to ADCs with alternative payloads. CR-002 is expected to initiate Phase 1 trials in 2026, with the target for the program to be disclosed as it approaches the clinic.

The merger between GlycoMimetics and Crescent Biopharma represents a significant opportunity for both companies and their stockholders. The combined company will have a robust pipeline of innovative cancer therapies, with the potential to improve outcomes for patients with solid tumors. The $200 million financing round, along with the operational funding expected to last through 2027, will support the advancement of Crescent Biopharma's pipeline and accelerate its development.




In conclusion, the merger between GlycoMimetics and Crescent Biopharma creates a new entity with a strong pipeline of innovative cancer therapies and a well-funded development plan. The combined company's focus on precision-engineered biologics and cooperative binding mechanisms positions it well to capitalize on the growing market for PD-1xVEGF bispecific opportunities. With the support of prominent investors and a strategic vision for growth, Crescent Biopharma is poised to make a significant impact on the cancer treatment landscape.